All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
CD79B (cluster of differentiation 79β) forms an essential component of BC (B-cell receptor) signaling pathway. It is important for the initiation of the signaling cascade upon interaction of the BCR with antigen. Its expression in absent in terminally differentiated plasma cells and its aberrant expression is linked with various B-cell malignancies, such as chronic lymphocytic leukemia. Mutations in this gene are involved in the pathogenesis of chronic lymphocytic leukemia (CLL). CD79B plays an essential role in the development of human B cells and mutations in this gene can result in agammaglobulinemia.
